NCT06078657View on ClinicalTrials.gov

IBI110 Combined With Sintilimab in Second-line Advanced or Metastatic Esophageal Squamous Cell Carcinoma(ESCC)

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

46

Participants

Timeline

Start Date

October 31, 2023

Primary Completion Date

October 31, 2024

Study Completion Date

October 31, 2025

Conditions
Esophageal Squamous Cell Carcinoma (ESCC)PD-1 Inhibitors
Interventions
DRUG

IBI110+Sintilimab

"IBI110, 200mg, intravenously on the first day of each cycle, every 3 weeks for 1 cycle (Q3W), and the maximum use time was 2 years.~Sintilimab, 200mg, intravenously on the first day of each cycle, every 3 weeks as a cycle (Q3W), and the maximum use time was 2 years."

Trial Locations (1)

450052

Feng Wang, Zhengzhou

All Listed Sponsors
lead

The First Affiliated Hospital of Zhengzhou University

OTHER